Wall Street Zen Upgrades ASP Isotopes (NASDAQ:ASPI) to Sell

ASP Isotopes (NASDAQ:ASPI) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $4.00 on Friday. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. The business has a fifty day simple moving average of $4.94 and a two-hundred day simple moving average of $5.31. The firm has a market cap of $613.24 million, a PE ratio of -3.03 and a beta of 3.61. ASP Isotopes has a twelve month low of $3.51 and a twelve month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last issued its earnings results on Friday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The business had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Insiders Place Their Bets

In other news, CFO Heather Kiessling sold 23,124 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.28, for a total value of $145,218.72. Following the sale, the chief financial officer directly owned 1,526,252 shares in the company, valued at approximately $9,584,862.56. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Robert Ainscow sold 8,438 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00. Following the completion of the sale, the chief operating officer directly owned 2,281,879 shares in the company, valued at approximately $15,973,153. The trade was a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 279,079 shares of company stock worth $2,049,208. Insiders own 14.40% of the company’s stock.

Institutional Trading of ASP Isotopes

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in shares of ASP Isotopes during the 1st quarter worth about $29,000. Quantbot Technologies LP acquired a new position in ASP Isotopes in the 3rd quarter worth about $34,000. BNP Paribas Financial Markets raised its holdings in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after purchasing an additional 2,548 shares during the period. Stephens Inc. AR purchased a new position in ASP Isotopes during the first quarter worth approximately $44,000. Finally, Broadhurst Jeffrey B purchased a new position in ASP Isotopes during the first quarter worth approximately $44,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.